ARVN Arvinas Inc
Price (delayed)
$17.95
Market cap
$1.23B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.77
Enterprise value
$1.14B
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing
Highlights
Arvinas's revenue has soared by 64% from the previous quarter
The gross profit has soared by 64% from the previous quarter
The quick ratio is up by 11% since the previous quarter but it has declined by 7% year-on-year
The company's equity fell by 15% YoY and by 4.1% QoQ
Key stats
What are the main financial stats of ARVN
Market
Valuations
Earnings
Shares outstanding
68.77M
Market cap
$1.23B
Enterprise value
$1.14B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.2
Price to sales (P/S)
4.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.34
Revenue
$263.4M
Gross profit
$263.4M
Operating income
-$250.2M
Net income
-$198.9M
EBIT
-$198.3M
EBITDA
-$191.7M
Free cash flow
-$261M
Per share
Balance sheet
Liquidity
EPS
-$2.77
EPS diluted
-$2.77
Free cash flow per share
-$3.63
Book value per share
$8.17
Revenue per share
$3.66
TBVPS
$15.18
Total assets
$1.09B
Total liabilities
$529.7M
Debt
$9.7M
Equity
$561.7M
Working capital
$837.5M
Debt to equity
0.02
Current ratio
4.64
Quick ratio
4.58
Net debt/EBITDA
0.47
Margins
Efficiency
Dividend
EBITDA margin
-72.8%
Gross margin
100%
Net margin
-75.5%
Operating margin
-95%
Return on assets
-16.7%
Return on equity
-33.7%
Return on invested capital
-24.5%
Return on capital employed
-23%
Return on sales
-75.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARVN stock price
How has the Arvinas stock price performed over time
Intraday
1.53%
1 week
-8.37%
1 month
-3.6%
1 year
-64.93%
YTD
-6.36%
QTD
-6.36%
Financial performance
How have Arvinas's revenue and profit performed over time
Revenue
$263.4M
Gross profit
$263.4M
Operating income
-$250.2M
Net income
-$198.9M
Gross margin
100%
Net margin
-75.5%
The net margin has surged by 84% year-on-year and by 61% since the previous quarter
Arvinas's operating margin has soared by 81% YoY and by 57% from the previous quarter
Arvinas's revenue has soared by 64% from the previous quarter
The gross profit has soared by 64% from the previous quarter
Growth
What is Arvinas's growth rate over time
Valuation
What is Arvinas stock price valuation
P/E
N/A
P/B
2.2
P/S
4.9
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.34
The EPS has soared by 58% YoY and by 42% from the previous quarter
The stock's price to book (P/B) is 49% less than its 5-year quarterly average of 4.3 and 31% less than its last 4 quarters average of 3.2
The company's equity fell by 15% YoY and by 4.1% QoQ
The P/S is 90% below the 5-year quarterly average of 48.7 and 75% below the last 4 quarters average of 19.6
Arvinas's revenue has soared by 64% from the previous quarter
Efficiency
How efficient is Arvinas business performance
The ROS has soared by 84% YoY and by 60% from the previous quarter
The company's return on invested capital has surged by 53% YoY and by 36% QoQ
ARVN's return on equity has surged by 52% year-on-year and by 33% since the previous quarter
ARVN's return on assets is up by 47% year-on-year and by 33% since the previous quarter
Dividends
What is ARVN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARVN.
Financial health
How did Arvinas financials performed over time
ARVN's total assets is 106% more than its total liabilities
Arvinas's total liabilities has decreased by 18% YoY and by 9% from the previous quarter
ARVN's total assets is down by 16% YoY and by 6% from the previous quarter
The debt is 98% smaller than the equity
The company's equity fell by 15% YoY and by 4.1% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.